Join

Compare · LAB vs RVTY

LAB vs RVTY

Side-by-side comparison of Standard BioTools Inc. (LAB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LAB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
  • RVTY is the larger of the two at $9.69B, about 26.5x LAB ($365.2M).
  • Over the past year, LAB is down 23.0% and RVTY is down 7.8% - RVTY leads by 15.2 points.
  • Both names hit the wire about 7 times in the past 4 weeks.
  • RVTY has more recent analyst coverage (18 ratings vs 5 for LAB).
PerformanceLAB-22.97%RVTY-7.79%
2025-05-02+0.00%2026-05-01
MetricLABRVTY
Company
Standard BioTools Inc.
Revvity Inc.
Price
$0.93+0.80%
$86.69+0.03%
Market cap
$365.2M
$9.69B
1M return
+1.00%
-1.41%
1Y return
-22.97%
-7.79%
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Laboratory Analytical Instruments
Exchange
NASDAQ
NYSE
IPO
2011
News (4w)
7
7
Recent ratings
5
18
LAB

Standard BioTools Inc.

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.